| Abstrakt: |
A recent study conducted by researchers at the Center for Molecular Immunology in Havana, Cuba, explored the effects of chemotherapy and a thymic polypeptide factor called Biomodulina T (BT) on non-classical lymphocyte populations in patients with advanced lung cancer. The study found that chemotherapy did not significantly alter the percentages of natural killer (NK), natural killer T cells (NKT), and double-positive T lymphocyte (DPT) populations in these patients. However, the administration of BT decreased DPTs and NK cells expressing the cluster of differentiation (CD)57 molecule, which is considered a marker of immunosenescence. These findings suggest that BT may have the potential to improve the response to cancer immunotherapies in patients with advanced lung cancer. [Extracted from the article] |
